Stem cell transport moves two different kinds of product: cord blood units banked from a newborn's umbilical cord and placenta, and apheresis collections, the concentrated stem cells drawn directly from a bone marrow donor's or a patient's own bloodstream. Cord blood is almost always frozen and banked for years before use. A fresh apheresis collection is often not frozen at all, it can move to the transplant center as a liquid product held cold for only a matter of hours before infusion. Those two products sit at opposite ends of the same shipping problem, one banked indefinitely, one racing a clock measured in hours.
Which path a given collection takes decides almost everything about how it ships, from the packaging it travels in to how far in advance a transplant center can plan the infusion date.
Cryogenic dry shippers for banked product
A cord blood unit or a cryopreserved apheresis collection ships in a dry shipper, an insulated vessel that holds liquid nitrogen vapor rather than the liquid itself, keeping the product below -150°C for days without any liquid nitrogen touching the sample directly. See cryogenic shipping for how that vapor-phase environment is maintained across a multi-day transit. Because the product is frozen solid and stable at that temperature, the shipping window is generous: a dry shipper charged correctly before departure holds its temperature far longer than the transit itself typically requires.
Cord blood banks test each unit's cell count and viability before freezing, since a unit with too few stem cells will not be usable for an adult transplant no matter how well it is shipped afterward. That quality check happens once, at banking, and the frozen unit then sits untouched in storage until a transplant center requests it, sometimes years later.
Fresh apheresis product runs on hours, not days
An uncryopreserved apheresis collection is a different problem entirely. The cells are alive and metabolically active, not frozen, so the product is packed cold in a hypothermic state, similar in principle to a 2-8°C shipment, and has to reach the transplant center and be infused within a window measured in single-digit hours rather than days. There is no dry-shipper buffer to fall back on if a flight is delayed, because refrigeration only slows the cells' decline, it does not stop it the way freezing does.
Donor-to-patient scheduling
A transplant center schedules the patient's conditioning regimen, chemotherapy or radiation that clears the way for the new cells, against the exact day the stem cell product is expected to arrive. For a fresh apheresis product, the collection appointment, the flight, and the infusion slot are booked as one continuous chain, because conditioning cannot be reversed once started and the patient has no functioning immune system until the new cells engraft. Banked cord blood removes most of that pressure since the unit already exists in frozen inventory, but even then the thaw and infusion have to be timed precisely once the transplant date is set.
A matched, unrelated donor adds another layer to that schedule. The donor's own apheresis appointment has to be booked, confirmed, and completed before the product can ship, and a donor who withdraws or falls ill close to the date leaves the transplant center searching for a backup with very little notice, after the patient's conditioning regimen may already be underway.
The cost of a missed window
Losing or delaying a fresh apheresis shipment is far more serious than losing an ordinary cold chain parcel, because the donor or patient may not be able to repeat the collection on short notice, and the recipient's conditioning regimen cannot simply be paused. This is why fresh product moves on dedicated couriers with continuous temperature monitoring rather than standard freight, and why transplant programs build schedule buffers around known chokepoints like customs holds and flight connections instead of assuming a shipment will move exactly on plan. Banked, cryopreserved product carries none of that same-day risk, which is the honest trade-off cord blood banking makes: a longer processing and storage cost upfront in exchange for a shipment that is far more forgiving in transit.
Not every collection needs the dedicated courier treatment either. A domestic shipment between an apheresis center and a transplant center a short drive apart does not carry the same routing risk as an international flight with a connection, and building the heaviest possible contingency plan around a low-risk local transfer spends money and staff time a longer, riskier route genuinely needs.
Cell therapy programs and blood banks
Apheresis centers collect the product, cord blood banks process and freeze donated units, and transplant centers, mostly hematology and oncology programs, schedule and receive the shipment. The dry-shipper equipment and courier networks used here overlap heavily with the broader blood cold chain, since blood banks and transplant centers often share staff, couriers, and monitoring standards. Some experimental stem cell protocols run inside a clinical trial supply chain instead of standard clinical care, adding trial-specific labeling and chain-of-custody paperwork on top of the same cold chain handling.